Page 1. Current Concepts: Etiology, Clinical Manifestations, and Treatment. Gary Schiller, MD
|
|
- Sarah Lee
- 8 years ago
- Views:
Transcription
1 Treating Higher-Risk Myelodysplasia Current Concepts: Etiology, Clinical Manifestations, and Treatment Gary Schiller, MD Presentations in Two Patients 86 y.o. male with a 6-y hx of macrocytic anemia referred for a fall in hgb from 10 to 8g/dl requiring monthly transfusion-support. P.E. without significant findings. P.B.: WBC12.7, Hgb 8.7 MCV 95.1, Plt 282K; BM showed RARS, karyotype: 45,X,-Y[2] 46,XY[18] 53 y.o. male with a 1-m hx of fatigue referred for evaluation of pancytopenia. P.E. revealed splenomegaly. P.B.: WBC 2.4, Hgb 7.2, plt 49K; BM showed RAEB, karyotype: 47,XY,+8[11]/46,XY[9] Myelodysplasia- Definition Catenacci DVT, Schiller, G: Blood Rev An oligoclonal disorder of hematopoiesis characterized by: Ineffective hematopoiesis Cytopenias Variable clonal cytogenetic abnormalities Variable tendency toward evolution to acute leukemia Page 1
2 Pathophysiology Bone Marrow Microenvironment Increased pro-apoptotic signals- soluble factors» TNF-α, VEGF Dysregulation of immune response» Over-expression of HLA-D15 Genomic Instability of the Clone Jackson et al., Nature 2002 Lachner, Current Biology 2002 Cytogenetic Abnl Distinct Cytogenetic Findings Olney HJ, LeBeau MM: Best Practice & Res. Clin. Haem. 14:479-95; 95; 2001 Percent of MDS/t- MDS Risk of progression to AML/prognosis Region of chromosome involved/gene Del 20 q 5% / 7% Low/ good Gene-rich CDS 20q11.2-q12 Monosomy Y - Low if isolated/good Monosomy 5/5qdel 10-20% / 40% High/poor Two separate CDS regions Monosomy 7/del7q 5% / 55% High/poor 7q22 and 7q p- 7% MDS High/poor Tumor-suppressor p53 11q23 5-6%/ 2-3% Intermediate/med. MLL gene Trisomy 8 10% MDS Intermediate/med. Unknown Complex karyotypes 10-20% / 90% High/poor Multiple 5 q - syndrome Low/good Q 31 and q 333 Page 2
3 Bone Marrow Findings in MDS Erythropoiesis Megaloblastic; nuclear cytoplasmic asynchrony Nuclear atypia of erythroid precursors» Budding nuclei, multi-lobed, multinuclear, etc. Ringed sideroblasts» Abnormal iron distribution/utilization Megakaryopoiesis Micromegakaryocytes Nuclear atypia» Mononuclear; multiple small nuclei Bone Marrow Findings in MDS Granulopoiesis Hyposegmented granulocytic precursors Psuedo Pelger-Huet cells Hypogranular granulocytes Loss of orderly maturation» maturation bulge = maturation arrest Abnormal increase in blasts Classification of MDS FAB classification WHO classification Page 3
4 Prognosis in MDS Shortened survival Infection Bleeding Progression to AML FAB categories poorly predict prognosis Recognizes role of excess blasts in determining outcome Wide range of outcomes/survival in each group Neglects role of cytogenetics, cytopenias Unclassifiable MDS Prognosis in MDS Identification of additional risk factors International Prognostic Scoring System Blasts Cytogenetics Cytopenias Survival Evolution to AML Cytogenetics Acquired chromosomal abnormalities are found in 40-60% of primary MDS patients Abnormalities in 80% of therapy-related MDS Alkylators induce multiple abnormalities, particularly in chromosomes 5 and 7 Topoisomerase inhibitors induce MLL gene fusions, usually involving 11q23 Page 4
5 International Prognostic Scoring System Points Marrow Blasts < 5% % % % 1.5 Cytopenias 0 or or Cytogenetics good (normal; 5q-; Y-; 20q-) 0 intermediate (others) 0.5 poor (7; or >3 abnormalities) 1.0 International Prognostic Scoring System Overall Score Median Survival Low Risk years Intermediate Intermediate High Risk > years 1.2 years 0.4 years International Prognostic Scoring System Overall Score Evolution to AML Low Risk years Intermediate Intermediate High Risk > years 1.1 years 0.2 years Page 5
6 Treatment of Myelodysplasia-- Difficulties in Assessing the Data Paucity of randomized trials Endpoints Cytopenias, transfusion requirement Survival Trial populations Age Prognostic group Baseline studies Inclusion of de novo AML Myelodysplasia Treatment Curative approaches Transplantation Disease control Low intensity therapy High intensity therapy Supportive care Hematopoietic growth factors Transfusion Antibiotics Iron chelation Risk-Adapted Therapy in Myelodysplastic Syndromes Appropriately identify and treat different subcategories of disease Identify high-risk disease in patients who are candidates for aggressive therapy Allogeneic stem cell transplant Cytotoxic chemotherapy Prognosticate Improve complications and quality of life Page 6
7 Intensive Chemotherapy in MDS Combination chemotherapy AML remission induction regimens» (anthracycline + cytarabine) with or w/out etoposide» Topotecan with or w/out cytarabine» Fludarabine with cytarabine» Decitabine in clinical trials <50% remission rates» 90% of patients relapse» Co-morbid disease Remission durations < 1 year» Bridge to autologous transplant Suitable for young patients Stem Cell Transplantation Myeloablative therapy High-dose chemotherapy + radiation Rescue infusion of hematopoietic stem cells Bone marrow Peripheral blood (apheresis) Umbilical cord blood Stem Cell Transplantation in Myelodysplasia Allo SCT outcome correlates with IPSS score 251 patients with MDS, FHCRC 5 year disease-free survival» 60% for low risk and intermediate-1 t» 36% for intermediate-2» 28% for high risk Allo SCT for intermediate or high risk patients Appelbaum & Anderson. Leukemia 1998;12 (Suppl 1): S25- S29 Autologous stem cell transplant Recovery of polyclonal hematopoiesis in some cases Page 7
8 Stem Cell Transplantation in Myelodysplasia Benefit (survival) exceeds risk for IPSS intermediate or high risk patients who are physiologically suitable for allogeneic transplant Non-myeloablative transplant Fludarabine, TBI preparative regimen Decreased regimen-related mortality Up to age 75 Azacytidine in Myelodysplasia Silverman LR, Demakos EP, Peterson BL et al. J Clin Oncol. 2002;20:2429 RNA and DNA methylation inhibitor given subcutaneously in monthly cycles Response rate and Survival compared to best- supportive care with potential to cross-overover Response Rate 23% vs. 0% Complete remission in 7% Response Duration 15 months with time-to-response of 64 days Diminished rate of transformation to AML but improvement in survival not significant Azacitidine: DNA Hypomethylation and Gene Activation DMT A : T C : G G : C mc : G G Aza C : C m DMT D M T A za A : T C : G G : C C : G G : C Azacitidine inhibition of DNA methyltransferase (DMT) results in hypomethylation. Hypomethylation may restore normal function to genes critical for differentiation and proliferation. Silverman, LR. The Oncologist. 2001;6(suppl 5):8-14. Page 8
9 Study 9221 A Randomized Phase III Controlled Trial of Subcutaneous Azacitidine in Myelodysplastic Syndromes RA RARS RAEB RAEB-T CMML S t r a t i f y No R 1) Supportive Exit a Care* Criteria + n Yes d o m i 2) Aza C 75mg/m z 2 /d x 7 days q28 x 4 e Continue until Endpoint + Aza C (dose as per arm #2) A S Response - Continue Rx S E No Response S - Off Study S M M M * Minimum duration of supportive care = 4 months unless Day M = Bone Marrow transform to AML; death or plts < 20 x 10 9 /L at week 8 or later Silverman L. The Oncologist (S5): Silverman LR, et al. J Clin Oncol. May 2002;20(10): Kornblith AB, et al. J Clin Oncol : Aza C Azacitidine S.C. Study 9221: Study Design A randomized, open-label, phase III study comparing the safety and efficacy of subcutaneous VIDAZA (azacitidine for injectable suspension) plus supportive care, versus supportive care alone 53 US sites Patients with any of the 5 FAB subtypes of MDS were included in the study. Patients with AML diagnosis were excluded from analysis (N=19). For purposes of assessing efficacy, the primary endpoint was response rate (CR+PR) Per protocol, patients achieving complete response (CR) with VIDAZA therapy were to receive 3 additional treatments before completing the study. VIDAZA full prescribing information. Study 9221: VIDAZA (azacitidine for injectable suspension) Dosing 75mg/m 2 SC daily x 7 days Cycles should be repeated every 4 weeks Recommended starting dose for the first treatment cycle, regardless of baseline hematology laboratory values is 75mg/m 2 SC daily for 7 days Dose could be increased to 100 mg/m 2 if no beneficial effect was observed after two treatment cycles, and no toxicity other than nausea and vomiting Premedicated for nausea and vomiting Page 9
10 Gender (n%) Male Female Race (n%) White Black Hispanic Asian/Oriental Age (years) N Mean ± SD Range Study 9221: Baseline Demographics Azacitidine (N=99) 72 (72.7) 27 (27.3) 93 (93.9) 1 (1.0) 3 (3.0) 2 (2.0) ± Observation (N=92) 60 (65.2) 32 (34.8) 85 (92.4) 1 (1.1) 5 (5.4) 1 (1.1) ± Study 9221: Baseline Characteristics Azacitidine (N=99) Observation (N=92) Adjudicated MDS diagnosis at study entry (n%) RA 21 (21.2) 18 (19.6) RARS 6 (6.1) 5 (5.4) RAEB 38 (38.4) 39 (42.4) RAEB-T 16 (16.2) 14 (15.2) CMMoL 8 (8.1) 7 (7.6) AML* 10 (10.1) 9 (9.8) Transfusion product used in 3 mos before study entry (n%) Any transfusion product 70 (70.7) 59 (64.1) Blood cells, packed human 66 (66.7) 55 (59.8) Platelets, human blood 15 (15.2) 12 (13.0) * Not intended to be included Study 9221: Additional Endpoints Improvement Benefit in peripheral counts not meeting criteria for PR Patients achieving at least a single lineage response defined as:» 50% restoration in the deficit from normal of baseline WBC, hemoglobin, or platelets (if abnormal at baseline) or» 50% reduction in PRBC or platelet transfusion requirements VIDAZA Transfusion requirements (azacitidine for injectable suspension) full prescribing information. Data on file, Pharmion Corporation. Page 10
11 Study 9221: Response Rates* VIDAZA (azacitidine for injectable suspension (N=89) Observation before Crossover (N=83) Response n (%) n (%) p-value Overall (CR+PR) 14 (15.7) 0 (0.0) < Complete (CR) 5 (5.6) 0 (0.0) 0.06 Partial (PR) 9 (10.1) 0 (0.0) --- *Excludes patients with adjudicated baseline diagnosis of AML Approximately 24% of Vidaza patients were considered improved VIDAZA (azacitidine for injectable suspension) full prescribing information. VIDAZA (azacitidine for injectable suspension): Proven treatment for MDS patients with excess bone marrow blasts According to the IPSS, excess blasts are the strongest predictor of poor outcomes More than half of all patients who participated in study 9221 had excess blasts prior to treatment Patients with RAEB or RAEB-T responded to VIDAZA therapy, as did those without excess blasts Patients who achieved CR had complete normalization of peripheral and bone marrow blasts Patients who achieved PR had a 50% or greater reduction in bone marrow blasts and no peripheral blasts VIDAZA full prescribing information. Data on file, Pharmion Corporation. Study 9221: Time to Response 90% of responding patients had an increase in platelets, hemoglobin, or WBC, or a decrease in bone marrow blasts by the 5 th cycle Achievement of PR was reported between the 2 nd and 19 th cycles Achievement of CR was reported between the 8 th and 15 th cycles PR or CR may require more than 4 treatment cycles with VIDAZA (azacitidine for injectable suspension) VIDAZA full prescribing information. Data on file, Pharmion Corporation. Page 11
12 Study 9221: Efficacy Summary Response was independent of FAB subtype Patients with RAEB or RAEB-T responded as did those without excess blasts Approximately half of all responding patients (CR or PR) achieved a trilineage response Responders experienced a decrease in bone marrow blasts, and/or an increase in platelets, hemoglobin, or WBC No overall differences in efficacy were observed between older patients and younger patients Survival benefit or delay in progression to AML, despite persistence of decreased bone marrow blasts percentages during PR or CR, could not be established for VIDAZA (azacitidine for injectable suspension) because cross over of control patients to the active treatment arm confounded these time-to-event end points Decitabine in Myelodysplasia Wijermans P, Lubbert M, Verhoef G, et al. J Clin Oncol. 2000;18:956 Potential Mechanism of Action Inhibition of methylation; targe may be p15 since hypermethylation of p15 is correlated with progression Unique characteristics Dose and Schedule Intravenously over 3 hours every 8 hours for three days each cycle Phase III Decitabine Study Design Open-label, 1:1 randomized, multi-center study in the US and Canada Eligible Patients (n = 170) R A N D O M I Z E D D St tifi ti Stratification IPSS Classification Prior Chemotherapy Study Center Decitabine + Supportive Care* (n = 89) Supportive Care* (n = 81) * Antibiotics, Growth Factors and/or Transfusions Page 12
13 Decitabine Dose and Administration Schedule: 3 hour infusion q 8 hrs x 3 days Three Consecutive Days 15 mg/m 2 3 hour 15 mg/m 2 3 hour 15 mg/m 2 3 hour 8 hours 8 hours 8 hours Cycle 135 mg/m 2 3 days 6 week cycle Median number of cycles/patient: 3 (Range = 1-9) Response* to Decitabine (ITT) IWG Response Rate, Onset & Duration Decitabine (n = 89) Supportive Care (n = 81) Overall Response Rate (CR+PR) 15 (17%)** 0 (0%) **p-value <0.001 from two-sided Fisher s Exact Test Onset & Duration of Response in Months Median time to (CR+PR+HI) response Median Duration of (CR+PR+HI) response 3.2 ( ) 9.5 ( ) Best response observed after 2 cycles (median number of cycles = 3) *IWG MDS criteria, Blood : Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in patients with myelodysplastic syndrome abstract 2515 Page 13
14 Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in patients with myelodysplastic syndrome abstract 2515 Myelodysplasia- final points. Therapeutic response to novel therapy and the need for new diagnostic groups (Schiller Leukemia 17: ; 1185; 2003) Clinical responses occur within a narrow statistical band for a variety of heterogeneous disorders Hematological improvement is typically erythroid Time to response is typically prolonged Response duration is not known Rarely, agents affect transformation, but not survival Future Directions in MDS Monoclonal antibodies Anti-CD33 conjugates Immunotherapy Vaccines Dendritic cells Differentiation therapy Other combination therapies Targeted therapies Must identify molecular targets! Farnesyltransferase inhibition Flt3 antagonists Page 14
15 Page 15
Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationEmerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
More informationRisk Stratification in AML. Michelle Geddes Feb 27, 2014
Risk Stratification in AML Michelle Geddes Feb 27, 2014 Objectives Outline the challenges in post-remission therapy for AML Review etiology of disease escape mechanisms from therapy Evaluate prognostic
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationMyelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma Hodgkin Lymphoma Overview Case Pathophysiology Diagnosis
More informationProject Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationMyelodysplasia. Dr John Barry
Myelodysplasia Dr John Barry Myelodysplasia Group of heterogenouus bone marrow disorders that are due to a defect in stem cells. Increasing bone marrow failure leading to quan>ta>ve and qualita>ve abnormali>es
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationHematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationPathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
More informationTherapy-related leukemia/myelodysplastic syndrome in multiple myeloma
Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma KAZUHIKO NATORI DAISUK NAGASE SUSUMU ISHIHARA AKIKO YUKITOSHI TOYODA MOTOHIRO KATO YOSINORI FUJIMOTO YASUNOBU KURAISHI HARUKA IZUMI
More informationCI-1. DACOGEN (decitabine) United States Food and Drug Administration Oncologic Drugs Advisory Committee February 9, 2012 NDA #21790/S-010
CI-1 DACOGEN (decitabine) United States Food and Drug Administration Oncologic Drugs Advisory Committee February 9, 2012 NDA #21790/S-010 CI-2 Introduction Alton Kremer, MD, PhD Senior Vice President,
More informationLEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova
LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationTreatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationAcute Myelogenous Leukemia Pre-HSCT Data
Instructions for Acute Myelogenous Leukemia Pre-HSCT Data (Form 2010) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the AML Pre-HSCT Data Form. E-mail
More informationTreating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationUnderstanding Myelodysplastic Syndromes: A Patient Handbook
UNITED STATES Understanding Myelodysplastic Syndromes: A Patient Handbook Sixth Edition the myelodysplastic syndromes foundation, inc. Published by The Myelodysplastic Syndromes Foundation, Inc. Understanding
More informationSecondary hematologic malignancies after chemotherapy. Sasha Stanton MD PhD February 14, 2014 Dr. Tony Blau Discussant
Secondary hematologic malignancies after chemotherapy Sasha Stanton MD PhD February 14, 2014 Dr. Tony Blau Discussant Case 1 Referral from Dr. Blau (Sibel) of a 60 yo woman 3 years out of therapy for her
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development
More informationStakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
More informationEISAI INC. FDA ODAC BRIEFING DOCUMENT NDA 021790/S-010. DACOGEN (decitabine) INDICATION: ACUTE MYELOID LEUKEMIA MEETING DATE: FEBRUARY 09, 2012
EISAI INC. FDA ODAC BRIEFING DOCUMENT NDA 021790/S-010 DACOGEN (decitabine) INDICATION: ACUTE MYELOID LEUKEMIA MEETING DATE: FEBRUARY 09, 2012 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationWhat Does My Bone Marrow Do?
What Does My Bone Marrow Do? the myelodysplastic syndromes foundation, inc. Illustrations by Kirk Moldoff Published by The Myelodysplastic Syndromes Foundation, Inc. First Edition, 2009. 2012. Table of
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationEvidence Review Group s Report
Evidence Review Group s Report Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Produced by Authors West Midlands Health Technology
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationAML: How to characterize and treat elderly patients non fit for standard chemotherapy
m1 AML: How to characterize and treat elderly patients non fit for standard chemotherapy Clinic for Medicine III University Hospital Munich Campus Grosshadern AMLCG study group Karsten Spiekermann, MD
More informationAr Mino changes including adjustment of therapy algorithms
cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationREFERENCE CODE GDHC003POA PUBLICAT ION DATE AUGUST 2013
REFERENCE CODE GDHC003POA PUBLICAT ION DATE AUGUST 2013 ACUTE MYELOID LEUKEMIA (AML) - Executive Summary AML: Key Metrics in Six Major Pharmaceutical Markets, 2012 2017 2012 Epidemiology Incident Population
More informationCharacteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET
Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET Lorenzo Falchi, Long Trinh, Edith M Marom, Mylene Truong, Ellen J Schlette,
More informationAcute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationControversies in the management of patients with PMF 0/1
State of the art treatments of patients with MPNs Turracher Höhe 2010 Controversies in the management of patients with PMF 0/1 Heinz Gisslinger Medical University of Vienna Divison for Hematology, Vienna
More informationAcute Myeloid Leukemia Therapeutics Market to 2020
Brochure More information from http://www.researchandmarkets.com/reports/3030124/ Acute Myeloid Leukemia Therapeutics Market to 2020 Description: Summary: Treatment and prognosis in AML is strongly influenced
More informationTherapy of AML. Contents. 1.1 Introduction... 1
Therapy of AML Elihu Estey Contents 1.1 Introduction... 1 1.2 Standard Therapy... 2 1.2.1 3+7... 2 1.2.2 Outcome Following 3+7... 2 1.2.3 Predictors of TRD... 2 1.2.4 Cytogenetics as the Principal Predictor
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationCytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
More informationSTUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan
STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationCytoreductive Therapy for Autologous Cell Therapy in HIV
Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor
More informationAcute Myelogenous Leukemia: A Guide for Patients and Caregivers
Acute Myelogenous Leukemia: A Guide for Patients and Caregivers LE UK E M I A Printing of this publication made possible by an education grant from LYMPHOMA M Y E L OM A Introduction Table of Contents
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationUnderstanding Myelodysplastic Syndromes: A Patient Handbook
Understanding Myelodysplastic Syndromes: A Patient Handbook Peter A. Kouides, MD John M. Bennett, MD Peter Kouides is Associate Professor of Medicine, University of Rochester School of Medicine and Dentistry,
More informationAPPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
More informationUniversity of California San Diego, January 31, 2015 Part 1 Page 1 of 22
University of California San Diego, January 31, 2015 Part 1 Page 1 of 22 Sandy Kurtin, RN, MS, AOCN, ANP-C Rafael Bejar, MD, PhD Dr. Rafael Bejar: Some of the questions you have will be questions that
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationAdult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
More informationTherapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation. Marianne E. McPherson Yee, MD, MSc
Therapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation Marianne E. McPherson Yee, MD, MSc Sickle Cell Treatment Options Supportive Care Newborn Screen PCN Immunizations Education
More informationMDS/AML and epigenetics
MDS/AML and epigenetics Moderator Prof.dr. J.H.E. Kuball 1st author / speaker Dr. G. Huls Belangenverklaring In overeenstemming met de regels van de Inspectie van de Gezondheidszorg (IGZ) Naam: Organisatie:
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationA Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly
Clinical Therapeutics/Volume 33, Number 3, 2011 A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly Dimitrios C. Ziogas, MD 1,2 ; Michael
More informationA Science Writer s Guide to Multiple Myeloma
A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationPhase I Trial Of Autologous Peripheral Blood Stem Cell Reinfusion For Those With Myelodysplastic Syndrome
Phase I Trial Of Autologous Peripheral Blood Stem Cell Reinfusion For Those With Myelodysplastic Syndrome Kyle Holen A. Objectives 1. To evaluate the toxicity of this chemotherapy regimen. 2. To evaluate
More informationI was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several
Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationACUTE MYELOGENOUS LEUKEMIA (AML)
Nicole Pearsall Clonal hematopoietic Disorders V Dr. Silberstein (#19) 9/23/03 The first 2 pages of Dr. Silberstein s notes are according to him the Gospel. This is what we are suppose to know for exam
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationSTEM CELL TRANSPLANTS
UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the
More informationBuilding A Focused Oncology Business
Building A Focused Oncology Business David Meek President, Oncology Our Strategic Priority: To be at the forefront of patient-centric innovation, bringing life-changing cancer therapies to patients with
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationMyeloablative conditioning regimens for the
ACUTE MYELOID LEUKEMIA What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Stephen J. Forman 1 1 Department of Hematology and Hematopoietic Cell Transplantation,
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationPoročilo EHA 2012. Simon Bitežnik
Poročilo EHA 212 Simon Bitežnik 1 Burden of chronic anaemia in patients with MDS Anaemia is a major clinical problem in patients with MDS ~8% patients are anaemic at diagnosis 1 In patients with MDS, anaemia
More informationWhy discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationYumi Yamamoto, 1 Akihito Kawashima, 2,3 Eri Kashiwagi, 1,3 and Kiyoyuki Ogata 1,3. 1. Introduction
Case Reports in Hematology, Article ID 141260, 4 pages http://dx.doi.org/10.1155/2014/141260 Case Report A Jehovah s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine:
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationOriginal Article Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus
Am J Blood Res 2013;3(2):141-164 www.ajblood.us /ISSN:2160-1992/AJBR1301001 Original Article Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus Joseph M Brandwein 1, Michelle
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationMyeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies
Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Robert J. Arceci, M.D., Ph.D. King Fahd Professor of Pediatric Oncology Professor of Pediatrics, Oncology and
More informationSonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
More information